CryoCath Freezor Tachycardia Approval Includes Cryomapping Indication
This article was originally published in The Gray Sheet
Executive Summary
CryoCath says it will pursue an expanded indication for its Freezor cardiac cryoablation system to address epicardial posteroseptal accessory atrioventricular pathways
You may also be interested in...
Atrial fibrillation trials
CryoCath gains FDA go-ahead to commence Phase I, 30-patient, three-center AF study using Arctic Circler Linear, Freezor Xtra and Freezor Max catheters. The Freezor cardiac cryoablation system was approved via PMA for atrioventricular node reentry tachycardia in April (1"The Gray Sheet" April 28, 2003, p. 5)...
Atrial fibrillation trials
CryoCath gains FDA go-ahead to commence Phase I, 30-patient, three-center AF study using Arctic Circler Linear, Freezor Xtra and Freezor Max catheters. The Freezor cardiac cryoablation system was approved via PMA for atrioventricular node reentry tachycardia in April (1"The Gray Sheet" April 28, 2003, p. 5)...
CryoCath Voluntary Catheter Replacement To Result In $1.5 Mil. Charge
CryoCath voluntarily will replace certain obsolete 7 Fr cryotherapy catheters that have demonstrated a breakage rate of less than 0.5% in over 4,000 procedures to date, the company says